|
Pharmaceutical companies spend billion of dollars each year performing clinical trials for the purpose of obtaining data about compounds/products. Such data is fully exploited in order to either achieve regulatory or marketing goals. We at SSI Strategy find it surprising that so many of these companies all but ignore the vast store of rich safety data in their pharmacovigilance database except to fulfill regulatory obligations.
Postmarketing safety data is continuously flowing into the company and provides rich insights about safe use of products. When analyzed correctly, this data can reveal insights that are capable of moving the needle for a company. In addition, we know that the industry is shifting its focus from efficacy to safety, indeed Safety is the New EfficacyTM. SSI Strategy has vast experience in carefully analyzing postmarketing safety data for purposes of building or supporting a commercial value proposition.
We can work with your team to ensure that you fully utilize this precious resource of data for more than simply meeting regulatory obligations. We will help you see how postmarketing safety data can be used to support the business in many ways.
We work with a very high integrity and high performing provider of publication services in order to support publications utilizing safety data.
|
